Get started
Author

Lourdes Anta

Observed names: L Anta, L. Anta, L. Anta Carabias, Lourdes A. Carabias, Lourdes Anta Carabias
ORCID: 0000-0001-5981-1850
Observed ORCID: 0000-0001-5981-1850
OpenAlex ID: A5012684643
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
2012 · Lourdes Anta, Josep M. Llibre, et al. · AIDS · 61
Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1)
2016 · Jordi Llaudó, Lourdes Anta, et al. · International Clinical Psychopharmacology · 27
Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study
2021 · Yuriy Filts, Robert E. Litman, et al. · Schizophrenia Research · 24
A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia
2017 · Lourdes A. Carabias, Jordi Llaudó, et al. · International Clinical Psychopharmacology · 24
All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997–2010
2013 · CoRIS cohort, Victoria Hernando, et al. · BMC Infectious Diseases · 24
PDF
HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines.
2009 · Carmen de Mendoza, Lourdes Anta, et al. · PubMed · 22
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study
2021 · David P Walling, Howard A Hassman, et al. · Drug Design Development and Therapy · 20
PDF
Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection
2012 · José Vicente Fernández-Montero, Eugenia Vispo, et al. · Expert Opinion on Pharmacotherapy · 18
Changing Rate of Non-B Subtypes and Coinfection with Hepatitis B/C Viruses in Newly Diagnosed HIV Type 1 Individuals in Spain
2010 · Ana Treviño, Vincent Soriano, et al. · AIDS Research and Human Retroviruses · 15
Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database
2010 · Eva Poveda, Lourdes Anta, et al. · AIDS · 15
Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain
2009 · Carmen De Mendoza, Carolina Garrido, et al. · AIDS Research and Human Retroviruses · 15
Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
2023 · Robert Litman, Dieter Naber, et al. · Neuropsychiatric Disease and Treatment · 14
PDF
Risperidone ISM ® : review and update of its usefulness in all phases of schizophrenia
2024 · Thomas Messer, Miquel Bernardo, et al. · Therapeutic Advances in Psychopharmacology · 11
Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes
2013 · L. Anta, J. L. Blanco, et al. · Journal of Antimicrobial Chemotherapy · 10
Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM®
2024 · Christian Laveille, Eric Snoeck, et al. · British Journal of Clinical Pharmacology · 9
PDF
Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy
2010 · Eva Poveda, Lourdes Anta, et al. · Antimicrobial Agents and Chemotherapy · 9
Newer Formulations of Risperidone: Remarks About Risperidone ISM®
2020 · Lourdes Anta, Elena Mata, et al. · CNS Drugs · 8
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults
2014 · M. Alvarez, S. Monge, et al. · Clinical Microbiology and Infection · 8
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy
2012 · Gilberto Betancor, César Garriga, et al. · Retrovirology · 8
PDF
Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients
2009 · Judit Morello, Carmen De Mendoza, et al. · Antimicrobial Agents and Chemotherapy · 8
Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM
2024 · Andreas Lindauer, Eric Snoeck, et al. · The Journal of Clinical Pharmacology · 6
PDF
Risperidone-ISM ® effectiveness and tolerability in acute schizophrenia patients hospitalised due to a relapse: results from an international, prospective, non-interventional evaluation (RESHAPE study)
2026 · Christoph U. Correll, Henrik Rohner, et al. · The World Journal of Biological Psychiatry · 4
PDF
Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations
2025 · Eric Snoeck, Nicolas Luyckx, et al. · Expert Review of Clinical Pharmacology · 4
Population pharmacokinetic modeling and simulations of dopamine Dd2 receptor occupancy of long-acting intramuscular risperidone-ISM
2016 · J. Llaudó, L. Anta, et al. · European Psychiatry · 3
PDF
Pharmacokinetics, safety, and tolerability of four 28-day cycle intramuscular injections for risperidone-ISM 75 mg in patients with schizophrenia: A phase-2 randomized study (PRISMA-2)
2016 · L. Anta, J. Llaudó, et al. · European Psychiatry · 2
PDF
Works count: 40
Citation count: 379
H-index: 12
I10-index: 14
Year
Topic
Type